Author

Ralf Mohrbacher

Observed names: Mohrbacher, Ralf, R Mohrbacher, R. Mohrbacher, RALF MOHRBACHER

Observed institutions: University of Calgary, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Sozialstiftung Bamberg, Dr Falk Pharma (Germany), University of Duisburg-Essen, Charité – Universitätsmedizin Berlin, University of Tübingen

ORCID: 0000-0002-4976-3629

Observed ORCID: 0000-0002-4976-3629

OpenAlex ID: A5047884604

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

2021 · Detlef Schuppan, Markku Mäki, et al. · New England Journal of Medicine · 241

PDF

Budesonide Is More Effective Than Mesalamine or Placebo in Short-term Treatment of Collagenous Colitis

2014 · Stephan Miehlke, Ahmed Madisch, et al. · Gastroenterology · 118

Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease

2010 · Andreas Tromm, Ivan Bunganič, et al. · Gastroenterology · 92

Clinical trial: A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis

2010 · Tilo Andus, Andreas Kocjan, et al. · Inflammatory Bowel Diseases · 66

Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease

2024 · Valeriia Dotsenko, Bernhard Tewes, et al. · Nature Immunology · 60

Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence

2017 · W. Kruis, V. Kardalinos, et al. · Alimentary Pharmacology & Therapeutics · 51

PDF

The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study

2014 · Wolfgang Kreisel, Peter Deibert, et al. · Digestive and Liver Disease · 51

Challenges and Opportunities in IBD Clinical Trial Design

2021 · Marla C. Dubinsky, Rory Collins, et al. · Gastroenterology · 35

Smoking Status Influences Clinical Outcome in Collagenous Colitis

2015 · Andreas Münch, Curt Tysk, et al. · Journal of Crohn s and Colitis · 35

Distribution of histopathological features along the colon in microscopic colitis

2020 · Anne-Marie Kanstrup Fiehn, Stephan Miehlke, et al. · International Journal of Colorectal Disease · 30

The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment

2023 · Jorma Isola, Markku Mäki, et al. · International Journal of Molecular Sciences · 29

PDF

Improvement in Oral Chronic Graft-versus-Host Disease with the Administration of Effervescent Tablets of Topical Budesonide—An Open, Randomized, Multicenter Study

2011 · Sharon Elad, Itai Zeevi, et al. · Transplantation and Cellular Therapy · 28

PDF

Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis

2018 · Wolfgang Kruis, Viacheslav Neshta, et al. · Clinical Gastroenterology and Hepatology · 25

UEG Week 2013 Oral Presentations

2013 · Kreisel, Wolfgang, Deibert, Peter, et al. · United European Gastroenterology Journal · 21

PDF

Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial

2022 · Wolfgang Kruis, Britta Siegmund, et al. · Journal of Crohn s and Colitis · 16

PDF

1052 Daily Mesalamine Fails to Prevent Recurrent Diverticulitis in a Large Placebo Controlled Multicenter Trial

2014 · Wolfgang Kruis, Vassilios Kardalinos, et al. · Gastroenterology · 16

808 Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial of Mesalamine for the Prevention of Recurrence of Diverticulitis

2013 · Wolfgang Kruis, Thomas Eisenbach, et al. · Gastroenterology · 16

Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo‐controlled multicentre trial

2021 · Andreas Münch, Emese Mihaly, et al. · United European Gastroenterology Journal · 11

PDF

Su1183 Topographical Distribution of Collagenous Colitis - A Pooled Histological Analysis of 2 European Prospective Multicenter Trials

2013 · Daniela E. Aust, Andreas Münch, et al. · Gastroenterology · 11

1158 Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, Multicenter Trial of Budesonide and Mesalamine in Collagenous Colitis

2012 · Stephan Miehlke, Ahmed Madisch, et al. · Gastroenterology · 10

391 Both Budesonide (9mg) As Well As High-Dose Eudragit-L-Coated Mesalamine (4.5g) Lead to High Remission Rates in Moderately Active Crohn's Disease Patients: A Double-Blind, Double-Dummy, Randomized, Multicenter Study

2009 · Andreas Tromm, Ivan Bunganic, et al. · Gastroenterology · 4

Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease

2026 · Valeriia Dotsenko, Hana Hien Le, et al. · BMC Medicine · 2

827: Transglutaminase 2 (tg2) Inhibitor Protects Gluten-induced Intestinal Damage in Celiac Disease: Transcriptomic Analysis of a Randomized Gluten Challenge Study

2022 · Valeriia Dotsenko, Juha Taavela, et al. · Gastroenterology · 2

Topographische Verteilung der Kollagenen Kolitis - eine gepoolte Analyse von 2 europäischen Multicenterstudien

2013 · S Miehlke, D Aust, et al. · Zeitschrift für Gastroenterologie · 2

P510 European multicenter trial of budesonide and mesalazine for short-term treatment of active collagenous colitis (BUC60/COC)

2013 · S. Miehlke, A. Madisch, et al. · Journal of Crohn s and Colitis · 2

Works count: 58

Citation count: 978

H-index: 16

I10-index: 20